600420.SS
Strong BuyUnloved QualityShanghai Shyndec Pharmaceutical Co., Ltd. · Healthcare · China · $1.6B
CNY 8.39 +2.2% · close 30 Sep · scored 3 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.
Read
Shanghai Shyndec Pharmaceutical, a subsidiary of China National Pharmaceutical Group (Sinopharm), specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. The company holds a leading position in anti-infective, cardiovascular, and endocrine therapeutic areas within China. Its integration into the massive Sinopharm distribution network provides a highly secure market channel and significant cost efficiencies.
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 13.0B | 12.1B | 10.9B | 9.4B | -10.3% | 8.4B |
| EPS (CNY) | 0.61 | 0.54 | 0.81 | 0.70 | 4.7% | 0.41 |
| Shares | 1.0B | 1.3B | 1.3B | 1.3B | +30.6% | 1.3B |
| Debt | 3.4B | 1.1B | 1.1B | 42.6M | -76.8% | 37.2M |
| Equity | 10.3B | 12.4B | 13.2B | 13.8B | 10.2% | — |
| Op CF | 2.9B | 1.7B | 2.3B | 1.7B | -15.9% | 1.1B |
| Inv CF | -302.4M | -1.4B | -856.2M | -2.4B | — | — |
| Fin CF | -435.3M | -1.1B | -415.4M | -1.6B | — | — |
Calmer than 87% of stocks we rank over the past year (22% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600420.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 600420.SS | Shanghai Shyndec Pharmaceutical Co., Ltd.(you) | $1.6B | 91 | Strong Buy |
| 600572.SS | Zhejiang CONBA Pharmaceutical Co.,Ltd. | $1.6B | 91 | Strong Buy |
| 600211.SS | Tibet Rhodiola Pharmaceutical Holding Co. | $1.8B | 90 | Strong Buy |
| 600216.SS | Zhejiang Medicine Co., Ltd. | $1.8B | 90 | Strong Buy |
| 600285.SS | Henan Lingrui Pharmaceutical Co., Ltd. | $1.6B | 87 | Strong Buy |
| 600750.SS | China Resources Jiangzhong Pharmaceutical Co.,Ltd | $2.1B | 92 | Strong Buy |
| 600993.SS | Mayinglong Pharmaceutical Group Co., Ltd. | $1.4B | 87 | Strong Buy |
| 002332.SZ | Zhejiang Xianju Pharmaceutical Co., Ltd. | $1.3B | 89 | Strong Buy |
| 600267.SS | Zhejiang Hisun Pharmaceutical Co., Ltd. | $2.0B | 95 | Strong Buy |
| 603456.SS | Zhejiang Jiuzhou Pharmaceutical Co., Ltd | $2.1B | 88 | Strong Buy |
Peer medians: ROE 4.3% · P/E 27.8x · Gross margin 53.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.